365 related articles for article (PubMed ID: 30068783)
1. Premature Clinical Trial Discontinuation in the Era of Immune Checkpoint Inhibitors.
Khunger M; Rakshit S; Hernandez AV; Pasupuleti V; Glass K; Galsky MD; Grivas P
Oncologist; 2018 Dec; 23(12):1494-1499. PubMed ID: 30068783
[TBL] [Abstract][Full Text] [Related]
2. Early Termination of Oncology Clinical Trials in the United States.
Zhang E; DuBois SG
Cancer Med; 2023 Mar; 12(5):5517-5525. PubMed ID: 36305832
[TBL] [Abstract][Full Text] [Related]
3. Estimating the rate and reasons of clinical trial failure in urologic oncology.
Stensland KD; DePorto K; Ryan J; Kaffenberger S; Reinstatler LS; Galsky M; Canes D; Skolarus TA; Moinzadeh A
Urol Oncol; 2021 Mar; 39(3):154-160. PubMed ID: 33257221
[TBL] [Abstract][Full Text] [Related]
4. Lack of timely accrual information in oncology clinical trials: a cross-sectional analysis.
Mitchell AP; Hirsch BR; Abernethy AP
Trials; 2014 Mar; 15():92. PubMed ID: 24661848
[TBL] [Abstract][Full Text] [Related]
5. Prevalence, characteristics, and predictors of early termination of cardiovascular clinical trials due to low recruitment: insights from the ClinicalTrials.gov registry.
Bernardez-Pereira S; Lopes RD; Carrion MJ; Santucci EV; Soares RM; de Oliveira Abreu M; Laranjeira LN; Ikeoka DT; Zazula AD; Moreira FR; Cavalcanti AB; Mesquita ET; Peterson ED; Califf RM; Berwanger O;
Am Heart J; 2014 Aug; 168(2):213-9.e1. PubMed ID: 25066561
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the Frequency, Characteristics, and Reasons for Termination of Spine-related Clinical Trials.
Caruana DL; Nam-Woo Kim D; Galivanche AR; David WB; Justen MA; Moushey AM; Sheth AH; Paranjpe MD; Grauer JN
Clin Spine Surg; 2022 Aug; 35(7):E596-E600. PubMed ID: 35351841
[TBL] [Abstract][Full Text] [Related]
7. Terminated Trials in the ClinicalTrials.gov Results Database: Evaluation of Availability of Primary Outcome Data and Reasons for Termination.
Williams RJ; Tse T; DiPiazza K; Zarin DA
PLoS One; 2015; 10(5):e0127242. PubMed ID: 26011295
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non-Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale.
Everest L; Shah M; Chan KKW
JAMA Netw Open; 2019 Jul; 2(7):e196803. PubMed ID: 31290990
[TBL] [Abstract][Full Text] [Related]
9. What Factors Are Associated with Clinical Trial Discontinuation in Orthopaedic Surgery: An Analysis of Clinical Trials Between 2007 and 2022.
Hecht CJ; Guyler MR; Shah A; Burkhart RJ; Kamath AF
J Bone Joint Surg Am; 2023 Oct; 105(19):1551-1559. PubMed ID: 37224236
[TBL] [Abstract][Full Text] [Related]
10. Noncompletion and nonpublication of trials studying rare diseases: A cross-sectional analysis.
Rees CA; Pica N; Monuteaux MC; Bourgeois FT
PLoS Med; 2019 Nov; 16(11):e1002966. PubMed ID: 31751330
[TBL] [Abstract][Full Text] [Related]
11. Unfinished business: Terminated cancer trials and the relevance of treatment intent, sponsors and intervention types.
Buergy D; Riedel J; Sarria GR; Ehmann M; Scafa D; Grilli M; Wenz F; Hofheinz RD
Int J Cancer; 2021 Apr; 148(7):1676-1684. PubMed ID: 33045097
[TBL] [Abstract][Full Text] [Related]
12. Assessing clinical trial failure risk factors and reasons in gastric cancer.
Zhang Z; Yin J; Yue Y; Su Y; Jiang H
BMC Gastroenterol; 2022 Nov; 22(1):496. PubMed ID: 36451088
[TBL] [Abstract][Full Text] [Related]
13. Early termination of cardiovascular trials as a consequence of poor accrual: analysis of ClinicalTrials.gov 2006-2015.
Baldi I; Lanera C; Berchialla P; Gregori D
BMJ Open; 2017 Jun; 7(6):e013482. PubMed ID: 28619765
[TBL] [Abstract][Full Text] [Related]
14. Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials.
Schroen AT; Petroni GR; Wang H; Gray R; Wang XF; Cronin W; Sargent DJ; Benedetti J; Wickerham DL; Djulbegovic B; Slingluff CL
Clin Trials; 2010 Aug; 7(4):312-21. PubMed ID: 20595245
[TBL] [Abstract][Full Text] [Related]
15. Understanding the Termination of Urologic Cancer Clinical Trials: Insights and Challenges.
Alhajahjeh A; Hmeidan M; Elatrsh M; Al-Abbadi F; Kakish D; Sukerji R; Salah M; Al Awamlh BAH; Lee DI; Shahait M
JCO Glob Oncol; 2024 Jan; 10():e2300349. PubMed ID: 38207249
[TBL] [Abstract][Full Text] [Related]
16. Completion and publication of clinical trials in a cooperative group: a cohort study of trials of the Swiss Group for Clinical Cancer Research (SAKK).
Hayoz S; Kasenda B; Schenker AL; Kopp C; Schär S; Thürlimann B; von Moos R; Pless M
BMJ Open; 2023 Apr; 13(4):e068490. PubMed ID: 37072360
[TBL] [Abstract][Full Text] [Related]
17. Reasons for and associated characteristics with early study termination: Analysis of ClinicalTrials.gov data on pregnancy topics.
Shieh C; Ofner S; Draucker CB
Nurs Outlook; 2022; 70(2):271-279. PubMed ID: 35090741
[TBL] [Abstract][Full Text] [Related]
18. Analysis of factors leading to early termination in glioblastoma-related clinical trials.
Shah HA; Mishra A; Gouzoulis MJ; Ben-Shalom N; D'Amico RS
J Neurooncol; 2022 Jul; 158(3):489-495. PubMed ID: 35648307
[TBL] [Abstract][Full Text] [Related]
19. Premature trial discontinuation often not accurately reflected in registries: comparison of registry records with publications.
Alturki R; Schandelmaier S; Olu KK; von Niederhäusern B; Agarwal A; Frei R; Bhatnagar N; Hooft L; von Elm E; Briel M
J Clin Epidemiol; 2017 Jan; 81():56-63. PubMed ID: 27614277
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the frequency, characteristics, and reasons for termination of shoulder- and elbow-related clinical trials.
Caruana DL; Gouzoulis MJ; McLaughlin WM; Grauer JN
J Shoulder Elbow Surg; 2022 Sep; 31(9):1922-1928. PubMed ID: 35398166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
